Insulin in Primary Care Dr Saqib Mahmud, MRCP(UK), MRCGP.

Slides:



Advertisements
Similar presentations
Insulin Therapy. Insulin Treatment (when?) Any Glucose Level Age Rapid onset Weight loss Tablets fail Pregnancy Illness Ketoacidosis Pancreat-ectomy.
Advertisements

Advanced Pumping. Objectives: Identify situations to utilize temporary basal rate in pump therapy patients. Identify examples of when to use combination.
Slides current until 2008 Nutritional needs of people with type 1 diabetes and type 2 diabetes.
Dr. Hemant Gupta [Associate Prof. & Unit Head, Dept of Medicine, J. J
Fylde Coast Integrated Diabetes Care
Diabetes Mellitus.
Insulin initiation OPTIMISING Glycaemic control and Weight Dr C Rajeswaran Consultant Physician Diabetes & Endocrinology Mid Yorkshire NHS Trust.
Insulin Pump What to tell your patient!! Prakash Abraham Isla Fairley.
BEDTIME INSULIN IN TYPE 2 DIABETES J. Robin Conway M.D. Diabetes Clinic, Smiths Falls,ON
Type 1 Diabetes Debbie McCausland Paediatric Diabetes Specialist Nurses.
The Disease: Type 1 diabetes is an auto-immune condition in which the immune system is activated to destroy the cells in the pancreas which produce insulin.
Dr Kiran Sodha Patient Participation Group October 2014
Richard Croft Diabetes Lead Berkshire West. The impact of a 1% reduction in HbA1c.
INSULIN STRATEGIES IN TYPE 2 DIABETES. The epidemic of type 2 diabetes and the recognition that achieving specific glycemic goals can substantially reduce.
Concepts in the natural history of diabetes.
Insulin therapy.
A joint investigation by Channel 4 News and the BMJ reveals the NHS spends tens of millions more than necessary on modern insulins to treat diabetes despite.
 Type one diabetes is a disease that takes place within your body and what it means is your body does not produce insulin. This is a problem because.
FACTS At least 194 m people worldwide suffer from diabetes; this figure is likely to be more than double by 2030 At least 194 m people worldwide suffer.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Drugs used in Diabetes Dr Sally Hudson. BIGUANIDES reduce output of glucose from the liver and enhances uptake and use of glucose by muscle cells ExampleADVANTAGESDISADVANTAGESCOSTCaution.
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
INSULIN THERAPY IN TYPE 1 DIABETES
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
BY: FARWA MOLOO U29/35723/2010 SUPERVISOR: DR AMUGUNE.
Guidelines for Diabetes Management September 20, 2012 Margaret Pochay RD CDE.
24 May How I Introduce Insulin in Type 2 Diabetes Mellitus Sheena Duffus Diabetes Specialist Nurse Norma Alexander Sister Diabetes Clinic.
Patient-directed titration to achieve glycaemic goals in type 2 diabetes using once-daily basal insulin: results of the TITRATE randomized controlled trial.
Glucose Control and Monitoring
Managing type-2 diabetes in primary care in south camden - a focus on insulin conversion.
Insulin Initiation In Primary Care Dr Arla Ogilvie Endocrinologist Watford General Hospital West Herts Hospitals NHS Trust.
Prevention Of Diabetes. Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic.
1 Diabetes-Where to from here ? Prepared by [Lynne Gilks] [CNC Diabetes Education] [Diabetes Centre, Tamworth] [November 2009]
What is Diabetes? Diabetes Specialist Team. AIMS AND OBJECTIVES Have an understanding of the physiology of Diabetes Risk factors and identifying the at.
18/11/20081 Diabetes mellitus Prepared by Thamer-almangour.
Insulin Elixir of life Dr. Sergio Diez Alvarez Staff Specialist Physician.
Technology to Assist with Diabetes Care February 4, 2011 Margaret Pochay RD CDE.
Dixie L. Thompson chapter 20 Exercise and Diabetes.
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
Should we be using the new insulins in T2DM? Ian Gallen MD FRCP Community Diabetologist Royal Berkshire Hospital.
Access to Quality Diabetes Education Act By Olga Ajpacaja.
Primary Care Prescribing for Type 2 Diabetes Dr. David Jenkins Worcestershire Royal Hospital.
FEW INFORMATION TO UNDERSTAND DIABETES.  What is Diabetes? What are the statistics?  What are the different types of Diabetes?  What are the symptoms?
Quality of Life Matters NOT TOO HIGH… NOT TOO LOW… A PLAN FOR OPTIMIZING DIABETES MANAGEMENT IN NURSING HOMES 5. Insulin: Part 1.
Diabetes Learning Event 7th October 2016
Management of Diabetes in the Older Person
Prevention Diabetes.
Most Mechanisms of B-Cell Damage (Hyperglycemia) Overlap with Causes of Vascular Disease : Provides Logic for Treatment Regimes and CV Benefits.
Non-Communicable Diseases Unit Lesson 3
Diabetes Mellitus.
Endocrine System KNH 411.
Endocrine System KNH 411.
Management of Diabetes in the Older Person
Insulin Safety know your insulins! There are many! Humalog® Mix25 Humalog® Mix50 Humulin® I Humulin® M3 Humulin® S Humalog® U-100 Humalog® U-200.
Monitoring in Type 2 Diabetes
Prevention Diabetes Dr Abir Youssef 29/11/2018.
Endocrine System KNH 411.
Insulin Use in Primary Care: Practice Challenges
Treatment Pathway for Adults with Type 1 Diabetes
Chapter 26 Endocrine Function
Diabetes Specialist Nurses
Endocrine System KNH 411.
Endocrine System KNH 411.
Endocrine System KNH 411.
Scenario 2.
Presentation and APA Essay
Type 2 Diabetes Subgroup
6.6 Hormones and homeostasis
Presentation transcript:

Insulin in Primary Care Dr Saqib Mahmud, MRCP(UK), MRCGP

Introduction Prevalence of DM in UK-2.2 million. Prevalence of DM in UK-2.2 million. 90%-T2DM 90%-T2DM Diabetic epidemic predicted to reach 300million by 2025 Diabetic epidemic predicted to reach 300million by 2025 Increased incidence of T2DM due to ageing population, sedentary life style & obesity Increased incidence of T2DM due to ageing population, sedentary life style & obesity T2DM results from insulin resistance & abnormal insulin secretion T2DM results from insulin resistance & abnormal insulin secretion

Insulin resistance Failure of peripheral tissues to respond or use insulin  prevents insulin signalling to the liver to reduce glucose production  hyperglycaemia hyperglycaemia

Abnormal insulin secretion Early phase  loss of rapid release of stored insulin in response to food Early phase  loss of rapid release of stored insulin in response to food Late phase  newly manufactured insulin becomes impaired  hyperglycaemia Late phase  newly manufactured insulin becomes impaired  hyperglycaemia

New approach to T2DM Mx Our approach has dramatically changed during the past few years Our approach has dramatically changed during the past few years Historically insulin was owned by health care professionals & self management of insulin was discouraged Historically insulin was owned by health care professionals & self management of insulin was discouraged Now, self management is actively encouraged with patient education & self adjustment on the start of therapy Now, self management is actively encouraged with patient education & self adjustment on the start of therapy Patients make the informed choice Patients make the informed choice

UKPDS Demonstrated beyond doubt  improved glycaemic control reduces microvascular complications Demonstrated beyond doubt  improved glycaemic control reduces microvascular complications T2DM runs a progressive course – 4% decline in beta cell function T2DM runs a progressive course – 4% decline in beta cell function Most patients will eventually need insulin to counteract beta cell failure Most patients will eventually need insulin to counteract beta cell failure Insulin is widely under used & frequently delayed particularly in primary care Insulin is widely under used & frequently delayed particularly in primary care

Reluctance to insulin Rx Stems from lack of confidence Stems from lack of confidence Practice factors Practice factors Patient factors Patient factors Insulin initiation interpreted as Rx failure rather than natural progression of disease Insulin initiation interpreted as Rx failure rather than natural progression of disease Current NHS developments are likely to expect insulin initiation largely in the primary care in future Current NHS developments are likely to expect insulin initiation largely in the primary care in future

Glycaemic control Various guidelines including UKPDS recommend HbA1c <7.5% Various guidelines including UKPDS recommend HbA1c <7.5% NICE - HbA1c b/w 6.5 to 7% NICE - HbA1c b/w 6.5 to 7% NSF Diabetes – HbA1c <7.5% NSF Diabetes – HbA1c <7.5% QoF target – HbA1c < or = 7.4% QoF target – HbA1c < or = 7.4%

Indications for Insulin initiation To maintain glucose control as beta cell failure progresses To maintain glucose control as beta cell failure progresses Progressive rise in HbA1c >7.5% despite max OHAs Progressive rise in HbA1c >7.5% despite max OHAs Osmotic symptoms Osmotic symptoms Sudden weight loss & intense tiredness Sudden weight loss & intense tiredness Painful peripheral neuropathy & diabetic Amytrophy Painful peripheral neuropathy & diabetic Amytrophy Episode of DKA Episode of DKA

Indications - continued MI (DIGAMI study) MI (DIGAMI study) Pregnancy Pregnancy Development of complications – most urgent need for insulin Development of complications – most urgent need for insulin

Barriers to initiate insulin Practice factors Reluctance to use insulin in T2DM Reluctance to use insulin in T2DM Reluctance by GPs to become involved in insulin initiation Reluctance by GPs to become involved in insulin initiation Traditionally insulin introduction was seen as a last resort Traditionally insulin introduction was seen as a last resort Need for referral to secondary care Need for referral to secondary care

Patient factors – reluctance to insulin Major barrier – widespread fear of self injecting / fear of needles Major barrier – widespread fear of self injecting / fear of needles Fear of hypoglycaemia- overestimate of risk Fear of hypoglycaemia- overestimate of risk Inability to deal with insulin- handle equipment, adjust dose Inability to deal with insulin- handle equipment, adjust dose Feeling of loss of health- insulin is seen as ‘beginning of the end’ Feeling of loss of health- insulin is seen as ‘beginning of the end’ Weight gain- levels off with time in most, counteracted by combining metformin, may not occur in some Weight gain- levels off with time in most, counteracted by combining metformin, may not occur in some

Patient factors - misconceptions Becoming ‘addicted to insulin’- once they start will be unable to stop it even if it does not suit them Becoming ‘addicted to insulin’- once they start will be unable to stop it even if it does not suit them Punishment for those who fail on other Rx Punishment for those who fail on other Rx Insulin causes ‘ill health’– usually from observations of others (particularly when insulin was introduced too late) leading to death or complications to follow Insulin causes ‘ill health’– usually from observations of others (particularly when insulin was introduced too late) leading to death or complications to follow ‘Live for today’- some prefer to live with increased risk of complications ‘Live for today’- some prefer to live with increased risk of complications Physical barriers – vision & dexterity Physical barriers – vision & dexterity

Assessing if insulin is appropriate Is the patient on max doses of OHAs with HbA1c>7% Is the patient on max doses of OHAs with HbA1c>7% Can the patient cope with daily injections or hypoglycaemia Can the patient cope with daily injections or hypoglycaemia Are the long term complications likely to occur in the patients life time Are the long term complications likely to occur in the patients life time Does the patient need an LGV or PCV license to work Does the patient need an LGV or PCV license to work Is the patient clinically obese Is the patient clinically obese

Common insulin regimes Once daily – basal with OHAs, eg; glargine or levemir Once daily – basal with OHAs, eg; glargine or levemir Twice daily pre-mixed insulins, eg; Novomix 30 Twice daily pre-mixed insulins, eg; Novomix 30 Multiple injections ( basal / bolus ) eg; glargine or levemir / novorapid – basal, once a day. Bolus, at meal times-tds Multiple injections ( basal / bolus ) eg; glargine or levemir / novorapid – basal, once a day. Bolus, at meal times-tds

Once daily- Basal with OHAs (glargine/ levemir) suitable for; Over weight& insulin resistant Over weight& insulin resistant Reluctant to start insulin Reluctant to start insulin Unable to inject themselves Unable to inject themselves Optimizing control is not vital but hypoglycaemia is unacceptable Optimizing control is not vital but hypoglycaemia is unacceptable Initiate at 10u or 0.2u/kg – dinner/bedtime, titrate dose 3-7 days Initiate at 10u or 0.2u/kg – dinner/bedtime, titrate dose 3-7 days Pre-breakfast BG levels are good indicators of their effectiveness Pre-breakfast BG levels are good indicators of their effectiveness

Twice daily pre-mixed insulins – good choice for; Fairly regular lifestyles, eat similar amounts at similar times each day Fairly regular lifestyles, eat similar amounts at similar times each day When OHAs are no longer sufficient to control BG levels after meals (becoming insulin depleted) When OHAs are no longer sufficient to control BG levels after meals (becoming insulin depleted) Eg;0.4x70kg=28u, start with 60% of this dose=16u, split 50/50 Eg;0.4x70kg=28u, start with 60% of this dose=16u, split 50/50 8 units am/pm titrate dose 8 units am/pm titrate dose

Multiple injections (basal/bolus) suitable for; Who need flexibility because of erratic life style, shift work, regular travelling across time zones, regular sport Who need flexibility because of erratic life style, shift work, regular travelling across time zones, regular sport Who need to optimize BG control b/c of complications, illness or wound Who need to optimize BG control b/c of complications, illness or wound Median daily dose s u/kg body wt Median daily dose s u/kg body wt Eg;0.4x70kg=28u Eg;0.4x70kg=28u 1/3 rd of total daily dose basal 1/3 rd of total daily dose basal 2/3 rd remaining bolus divide b/w 3 main meals 2/3 rd remaining bolus divide b/w 3 main meals

Conclusion Most individuals with T2DM will require insulin eventually due to disease progression and beta cell failure Most individuals with T2DM will require insulin eventually due to disease progression and beta cell failure Patients should be informed of this at initial diagnosis and not allowed to believe that need for insulin is a result of failure on their part to control the disease Patients should be informed of this at initial diagnosis and not allowed to believe that need for insulin is a result of failure on their part to control the disease